Context Therapeutics announces positive responses in Phase 2 OATH clinical trial
News release
by
Context Therapeutics
New York
|
February 07, 2023 12:21 PM Eastern Standard Time
Context Therapeutics CEO Marty Lehr joined Proactive's Natalie Stoberman to announce two clinical responses from its Phase 2 OATH Clinical Trial.
Lehr said two patients have achieved a confirmed partial response among the first 12 patients enrolled in the trial evaluating the potential of ONA-XR in combination with anastrozole to treat hormone receptor-positive metastatic endometrial cancer.
The findings are encouraging as ONA-XR exhibits initial signals of clinical activity and confirmed tumor shrinkage, Lehr added.
Contact Details
Proactive Investors USA
+1 347-449-0879
